Study sees no tie between Merck's Gardasil and VTE risk; Judge again smacks down Zohydro restrictions;

@FiercePharma: Biogen prices new, long-acting hemophilia med with eye on patient-switching. Story via FiercePharmaMarketing | Follow @FiercePharma

@EricPFierce: Health Canada tells GSK to get its vaccine house in order as flu season approaches. More | Follow @EricPFierce

@CarlyHFierce: Report: Cancer immunotherapy market to hit $9B by 2022. Item | Follow @CarlyHFierce

> Facing restrictions on OTC sales of antibiotics, Vietnam's largest drugmaker,DHG Pharmaceutical, plans to expand exports into Myanmar. Story

> Lobbying pressure from drugmakers and biotechs may have forced a U.S. senator to drop a bill addressing patent trolls. Report

> A new study found no evidence of a link between Merck's ($MRK) HPV vaccine Gardasil and higher risk for venous thromboembolism (VTE) in the period following vaccination. More

> A federal judge has again stepped on efforts by Massachusetts Gov. Deval Patrick to restrict sales of the opioid drug Zohydro. Story

Medical Device News

@FierceMedDev: Proteome Sciences, U.K. academics spot 10 Alzheimer's predictive biomarkers in blood. FierceDiagnostics story | Follow @FierceMedDev

@StacyALawrence: Surgeons tout benefits of Google Glass in operating room. More | Follow @StacyALawrence

@VarunSaxena2: Check out our special report on the top 10 highest paid med tech CEOs. | Follow @VarunSaxena2

@MichaelGFierce: MIT, MicroCHIPS develop remote-controlled contraceptive with on-off delivery. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Volatile compounds in fruits influence our perception of taste and smell, could trick us into healthy eating. Wired story | Follow @EmilyWFierce

> India may alter medical device taxation that favors imports. Item

> Zimmer, Biomet hit regulatory speedbump in pending merger. Story

> NeuroMetrix gains on FDA clearance of over-the-counter wearable, chronic pain device. Article

Biotech News

@FierceBiotech: Trending on FierceDrugDelivery: @MIT, MicroCHIPS develop remote-controlled contraceptive with on-off delivery. Story | Follow @FierceBiotech

@JohnCFierce: After a taste of disaster, Reata plans a comeback for bardoxolone - in Ph2 for PAH now after CKD blowup. News | Follow @JohnCFierce

@DamianFierce: Bernstein's Porges: "Wouldn't hold our breath" for any meaningful AS revenue from CELG's apremilast. More | Follow @DamianFierce

@EmilyMFierce: Oops: Smallpox discovered sitting in Maryland storage room. Story via The Washington Post | Follow @EmilyMFierce

> Sanofi ups the legal ante to block Lilly's Lantus biosimilar. Report

> International brouhaha over AbbVie misstep highlights U.K.'s M&A rules. Item

> Antibody expert arGEN-X pulls off a $54.5M IPO. News

> NIH sickle cell partner AesRx moves up the food chain in Baxter buyout. More

> After a taste of disaster, Reata plans a comeback for bardoxolone. Story

Drug Delivery News

> Researchers develop new chemo that targets mitochondrial DNA. Report

> Sanofi Pasteur taps CureVac for its RNA vaccine tech. Story

> InSite plans 2015 FDA submission for inflammation eye drop with suspended delivery. News

> Vaginal ring achieves localized, sustained release of anti-HIV drugs. More

> MIT, MicroCHIPS develop remote-controlled contraceptive with on-off delivery. Article

Diagnostics News

> U.K. company readies jump into bustling prenatal Dx market. Article

> NIH gives Kansas City startup $3M to come up with a quicker sepsis Dx test. More

> UC San Diego biomarker discovery could boost brain cancer drug's success rate. Story

> With funding secured, Definiens CEO Heydler talks about hoped-for digital tissue Dx boom. Article

> Proteome Sciences, U.K. academics spot 10 Alzheimer's predictive biomarkers in blood. Report

Pharma Marketing News

> Which big brands will still be bringing in the big bucks in 2020? Report

> Merck reaches doctors in India with online teaching tool. More

> Biogen prices new, long-acting hemophilia med with eye on patient-switching. Article

> Report: Cancer immunotherapy market to hit $9B by 2022. Item

> Is a price war imminent when Sanofi's Lantus patent falls? Story

And Finally... The most recent revision of the Declaration of Helsinki weakens protections for trial participants in low- and middle-income countries, researchers say. Story

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.